Literature DB >> 12801429

An approach to chronic fatigue syndrome in adults.

Thomas D Sabin1.   

Abstract

BACKGROUND: The neurologist is often asked to evaluate patients with a chief complaint of fatigue. Many neurologists do not believe in the pathologically based disease known as chronic fatigue syndrome, yet as a group, neurologists are well suited to guide the diagnostic work up of such patients to pinpoint treatable disorders in the realm of neurology, general medicine, and psychiatry. REVIEW
SUMMARY: Every patient should be carefully evaluated for certain medical, psychiatric, and neurologic disease that can cause fatigue as the most prominent symptom. This is most pressing because new work in virology, immunology, and imaging holds promise but still does not provide any diagnostic test or a mechanism for the production of these symptoms. Only a few treatments meet with even modest success in CFS. The goal of this paper is to provide the clinical neurologist with a framework for the investigation and management of this challenging group of patients.
CONCLUSIONS: Neurologists are typically also trained in psychiatry and general medicine, and this is a strong position to evaluate the patient with fatigue. Because no presently available test can make the diagnosis of CFS, the assessment is vital to seek out more treatable illnesses.

Entities:  

Mesh:

Year:  2003        PMID: 12801429     DOI: 10.1097/01.nrl.0000038586.58012.4c

Source DB:  PubMed          Journal:  Neurologist        ISSN: 1074-7931            Impact factor:   1.398


  2 in total

1.  Chronic fatigue.

Authors:  Prasanta Padhan
Journal:  CMAJ       Date:  2006-08-15       Impact factor: 8.262

2.  The effects of disease severity, use of corticosteroids and social factors on neuropsychiatric complaints in severe acute respiratory syndrome (SARS) patients at acute and convalescent phases.

Authors:  Bun Sheng; Sammy Kin Wing Cheng; Kwok Kwong Lau; Ho Lun Li; Eric Lok Yiu Chan
Journal:  Eur Psychiatry       Date:  2005-05       Impact factor: 5.361

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.